GAINING FROM BRANDS AND VOLUMES - AUROBINDO PHARMA

Article Abstract:

Aurobindo Pharma Ltd (APL) makes semi-synthetic penicillin (SSP) drugs. In 1997-98, it expanded its field force to 350 for promotion of branded formulations. APL exports oral and sterile SSP as bulk drugs. It exports drug intermediates like CMIC chloride, DCMIC chloride and 4methyl peperidione derivatives. It has six integrated facilities for production of bulk drugs, intermediates and formulations. It has an installed capacity for 2,135 tonnes per annum for bulk drugs and intermediates and 400 million units per annum for capsules and tablets. The company will be launching a wide range of cephalosporin drugs from its new facility which is under trial production. APL is setting up two wholly owned subsidiaries in the US and Hong Kong to increase its presence in the global market. It is projected to post sales of Rs525 crore and a net profit of Rs46-47 crore in 1998-99. (rk)(m)

United States, Hong Kong, Parent-to-subsidiary activities, Systemic Antibiotic Preparations, Antibiotics, Aurobindo Pharma Ltd.

---

LUPIN TO GAIN FROM CEPHALOSPORINS GOING OFF-PATENT

Article Abstract:

Lupin Laboratories will benefit from cephalosporins going off- patent in Europe in August 1998. It will now be able to sell its generic version of the drug and will be the only company in Europe other than Hoechst Marion Roussel. The company has projected that it will take a 10 percent share of the cephalosporins market in 18 months. The company says that three injectible cephalosporins will bring it about $50 million from Europe by 2002 AD. (khr)

Comment:

Will start marketing its generic version of cephalosporins in Europe starting 8/98

Europe, Cephalosporin Preparations, Cephalosporins, Article

---

LUPIN, MOVA SIGNS JV; BUYS ELI LILLY'S UNIT IN PUERTO RICO

Article Abstract:

Lupin Holdings Luxembourg, a subsidiary of Lupin Laboratories, has entered into a tie-up with MOVA Pharmaceutical Corporation (MOVA) of Puerto Rico. CEPH International Corporation (CIC), the joint venture company, will produce oral cephalosporin. It has also bought the oral cephalosporin formulation facility of Eli Lilly in Puerto Rico. CIC plans to make sales of $200 million in the first 3 years of its operations. (ag)

Asset sales & divestitures, Acquisitions & mergers, Drugs & Pharmaceuticals, Pharmaceutical and Medicine Manufacturing, Joint ventures, Puerto Rico, Drugs, Eli Lilly and Co., LLY, MOVA Pharmaceutical Corp., CEPH International Corp.

Similar abstracts:

• Abstracts: `WE AT VOLVO ARE LOOKING AT VERY MODEST VOLUMES'. VOLVO TO LAUNCH SECOND TRUCK MODEL FL7 IN FEB. RIDING THE FAST TRACK - THE VOLVO WAY
• Abstracts: THREE INDIAN COS HEAD FOR SRI LANKA ANDHRA MARKET FAILS TO ABSORB HIKE IN PRICES. ACC
• Abstracts: CERC TEST FINDS ASPIRIN BRANDS SUBSTANDARD. NPPA REVISES RIFAMPICIN PRICES
• Abstracts: CENTRE TO AMEND MRTP ACT TO MATCH CORPORATE NEEDS. NO TAX ON BUYBACK INCOME
• Abstracts: SASI ADVERTISING DRAWS UP PLANS TO DOUBLE BILLINGS ODYSSEY PLANS FORAY INTO NET AD

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.